Tadalafil (Generic) vs Vardenafil (Levitra/Staxyn): Side-Effect Profile Head-to-Head

How Tadalafil and Vardenafil Work, and Why That Shapes Side Effects

Both drugs inhibit phosphodiesterase type 5, the enzyme that breaks down cyclic GMP in penile smooth muscle, allowing sustained vasodilation and erection after sexual stimulation [1]. The mechanism is shared. What differs is selectivity for related PDE isoforms, plasma half-life, and the downstream tissues affected, three variables that explain most of the between-drug differences in adverse events.

PDE Isoform Selectivity

Tadalafil inhibits PDE11 (found in skeletal muscle and the testes) roughly 10-fold more than vardenafil does [2]. That cross-reactivity is the accepted pharmacological explanation for tadalafil's distinctive back pain and myalgia signal. Vardenafil is a more selective PDE5 inhibitor but shows measurable PDE6 inhibition in retinal photoreceptors, which may explain rare visual disturbances [3].

PDE6 inhibition also appears with sildenafil. Vardenafil's PDE6 affinity sits between sildenafil and tadalafil, so transient color-vision changes occur but are less common than with sildenafil at comparable therapeutic doses [4].

Half-Life and Duration

Tadalafil's half-life of approximately 17.5 hours means the drug remains pharmacologically active for up to 36 hours, earning the brand name "the weekend pill" [5]. Vardenafil's half-life is 4 to 5 hours, producing a more time-limited window of roughly 4 to 6 hours [6].

That duration difference carries a practical safety implication. Side effects from tadalafil, particularly back pain and flushing, may persist longer than those from vardenafil. A patient with a mild headache after vardenafil can expect resolution within 4 to 6 hours; the same headache after a 20 mg tadalafil dose may linger into the following morning.

Shared Side Effects: What Both Drugs Cause

The FDA-approved labeling for both tadalafil and vardenafil lists the same class-effect adverse reactions, because both agents dilate blood vessels systemically, not only in penile tissue [7, 8].

Headache and Flushing

Headache is the most common adverse event for both drugs. Pooled data across Phase III vardenafil trials showed headache in 15% of men taking 10 mg and 21% of men taking 20 mg [6]. Tadalafil Phase III data reported headache in 11 to 15% of on-demand users at 10 to 20 mg doses [5].

Flushing rates are similar: roughly 10 to 14% with vardenafil 10 to 20 mg and 4 to 11% with tadalafil 10 to 20 mg [5, 6]. The slightly lower flushing rate with tadalafil at equivalent efficacy doses is one frequently cited reason patients prefer it for long-term use.

Nasal Congestion and Dyspepsia

Nasal congestion occurs in approximately 9 to 11% of vardenafil users and 3 to 9% of tadalafil users [5, 6]. Dyspepsia is more distinctive for tadalafil (up to 10% at 20 mg) compared to vardenafil (1 to 4%), likely because tadalafil also inhibits PDE5 in esophageal smooth muscle, reducing lower esophageal sphincter tone [9].

Dizziness and Hypotension

Both drugs lower systolic blood pressure by 5 to 8 mmHg on average in healthy volunteers [7, 8]. This additive effect with other antihypertensives or with alpha-blockers is the dominant mechanism behind clinically significant dizziness and syncope. The FDA label for both drugs includes specific warnings about concomitant alpha-blocker use and mandates a minimum time interval before dosing [7, 8].

Tadalafil-Specific Side Effects

Back Pain and Myalgia

This is the clearest between-drug difference. Back pain and myalgia occur in approximately 5 to 6.5% of men taking tadalafil 10 to 20 mg on demand, compared to less than 2% with vardenafil [5, 10]. The Brock et al. (J Urol 2002) trial, which characterized tadalafil's longer duration relative to sildenafil, also documented this skeletal-muscle signal and attributed it to PDE11 inhibition in striated muscle tissue [10].

The back pain typically appears 12 to 24 hours after dosing, is described as dull and bilateral, and resolves without treatment within 48 hours in most patients [5]. Switching to daily low-dose tadalafil (2.5 to 5 mg) often reduces this adverse effect, because steady-state concentrations are lower and more stable than the peak after a single 20 mg dose [11].

Prolonged Duration as a Double-Edged Feature

The 17.5-hour half-life means any side effect that appears can last well into the next day. For patients who experience flushing, rhinorrhea, or indigestion, that extended duration is a drawback. Clinicians at HealthRX routinely advise patients starting tadalafil for the first time to take their first dose on a Friday evening so any lingering effects occur over a low-activity weekend rather than during a work day.

Vardenafil-Specific Side Effects

QTc Prolongation

This is vardenafil's most clinically important unique risk. Vardenafil prolongs the cardiac QT interval in a dose-dependent manner [8, 12]. In a thorough QT study, vardenafil 10 mg produced a mean QTc increase of approximately 8 milliseconds, and 80 mg (supratherapeutic) produced approximately 10 ms [12].

The FDA label explicitly contraindicates vardenafil in patients taking Class IA antiarrhythmics (quinidine, procainamide) or Class III antiarrhythmics (amiodarone, sotalol) [8]. Tadalafil does not carry an equivalent QTc warning, making it the preferred PDE5 inhibitor in patients with stable arrhythmias who require these medications and have been cleared for sexual activity by a cardiologist.

Food Interaction

A high-fat meal reduces vardenafil's maximum plasma concentration (Cmax) by approximately 18 to 50% depending on fat content, slowing absorption and delaying onset [6]. Tadalafil shows no clinically meaningful interaction with food, including high-fat meals [5]. For patients who prefer to take their ED medication with dinner, tadalafil is a more predictable option.

Vision Changes

Transient visual disturbances, primarily altered color discrimination or increased light sensitivity, occur in approximately 1 to 2% of vardenafil users [6]. The mechanism is PDE6 inhibition in retinal photoreceptors. These effects are dose-dependent and resolve as the drug clears. Patients with retinitis pigmentosa, which involves a genetic defect in retinal PDE, should avoid all PDE5 inhibitors, but the FDA label for vardenafil specifically mentions this population [8].

Head-to-Head Efficacy: What Comparative Trials Tell Us

No large prospective randomized controlled trial has directly compared tadalafil and vardenafil side-by-side in a single population with identical methodology. The comparative data come from cross-trial analysis, network meta-analyses, and patient-preference studies.

Diabetic ED: The Porst et al. Evidence

Porst et al. (Int J Impot Res 2003) evaluated vardenafil in men with diabetes mellitus, a population with notoriously treatment-resistant ED due to combined neurogenic and vasculogenic mechanisms [13]. At 10 mg and 20 mg, vardenafil produced significant improvements in IIEF erectile function domain scores versus placebo (P<0.001), with a side-effect profile consistent with the broader vardenafil clinical program [13]. Comparable diabetic ED trials for tadalafil have shown similar efficacy, suggesting neither drug holds a clear advantage in this difficult population [14].

Network Meta-Analysis Data

A 2017 network meta-analysis published in European Urology (N = over 150 trials, more than 50,000 patients) ranked vardenafil and tadalafil similarly on IIEF scores at on-demand doses, with no statistically significant difference between them in overall efficacy [15]. Tadalafil's daily 5 mg dose showed a sustained efficacy benefit in men with concurrent lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH), the only PDE5 inhibitor with FDA approval for both ED and BPH-LUTS [7].

LUTS and BPH: A Tadalafil-Only Indication

The Brock et al. Findings on tadalafil's prolonged duration align with its later FDA approval for BPH-LUTS at 5 mg daily [10]. Vardenafil has no approved indication for BPH-LUTS. Men with both ED and BPH-LUTS have one pharmacological reason to prefer tadalafil: one pill manages both conditions [7, 11].

Drug Interactions: Where the Two Drugs Diverge Most

Nitrates, Absolute Contraindication for Both

Both tadalafil and vardenafil are absolutely contraindicated with organic nitrates in any form, including nitroglycerin tablets, nitrate patches, and isosorbide preparations [7, 8]. The combination produces potentially fatal hypotension. This rule applies to poppers (amyl or butyl nitrite) as well. No dose adjustment resolves this interaction, the drugs simply cannot be co-administered.

Alpha-Blockers

Both drugs can produce additive hypotension with alpha-blockers (tamsulosin, doxazosin, terazosin). The vardenafil label specifically warns against concomitant use with tamsulosin 0.4 mg except under medical supervision [8]. Tadalafil 5 mg daily at steady state was studied with tamsulosin and showed acceptable hemodynamic profiles in most patients [7].

CYP3A4 Inhibitors

Both drugs are metabolized by CYP3A4. Strong inhibitors like ketoconazole, itraconazole, ritonavir, and clarithromycin significantly increase plasma concentrations of both drugs [7, 8]. With ritonavir, the tadalafil label caps the dose at 10 mg every 72 hours; with vardenafil, ritonavir co-administration is contraindicated entirely [8]. That is a meaningful clinical distinction for patients on HIV protease-inhibitor regimens.

Antiarrhythmics, Vardenafil Only

As noted above, vardenafil's QTc signal creates a hard contraindication with Class I and III antiarrhythmics that does not exist for tadalafil [8]. A patient stabilized on amiodarone for atrial fibrillation who also has ED should not receive vardenafil. Tadalafil, after cardiology clearance for sexual activity, remains an option.

Dosing Comparison and Practical Prescribing

Tadalafil Dosing Options

Tadalafil is available as generic tablets at 2.5, 5, 10, and 20 mg [7]. On-demand dosing starts at 10 mg, taken at least 30 minutes before sexual activity; the dose adjusts to 5 mg or 20 mg based on response and tolerability. Daily dosing at 2.5 to 5 mg provides a continuous low-level drug effect, removing the need to time intercourse and reducing peak-concentration side effects like back pain.

The on-demand 20 mg dose produces the highest peak concentrations and the most frequent adverse events. Patients who experience intolerable side effects at 20 mg should try 10 mg before switching drugs entirely [11].

Vardenafil Dosing Options

Standard vardenafil (Levitra) comes in 5, 10, and 20 mg tablets, taken 25 to 60 minutes before activity [6]. Staxyn is a 10 mg orally disintegrating tablet that absorbs without water, reaching Cmax roughly 15 minutes faster than the conventional tablet. Staxyn should not be substituted milligram-for-milligram for Levitra because Staxyn produces higher plasma concentrations at the same stated dose [8].

No daily low-dose vardenafil formulation has FDA approval. This limits vardenafil's utility in men who prefer continuous coverage or who have BPH-LUTS alongside ED.

Age and Renal/Hepatic Dose Adjustments

Men over 65 show higher vardenafil plasma concentrations; starting at 5 mg is recommended [6]. Tadalafil requires no starting-dose adjustment solely for age, though renal and hepatic impairment cap the maximum dose for both drugs [7]. In moderate hepatic impairment (Child-Pugh B), vardenafil should not exceed 10 mg per 24 hours; tadalafil should not exceed 10 mg per 72 hours [7, 8].

Which Drug Fits Which Patient Profile

Not every patient is an identical candidate. The clinical picture below is drawn from the prescribing literature and should be confirmed with a licensed prescriber who reviews your complete medical history.

Prefer tadalafil generic if:

• You want on-demand flexibility up to 36 hours or daily dosing without scheduling around meals
• You have concurrent BPH-LUTS requiring a single medication for both conditions
• You are on ritonavir-based antiretroviral therapy (tadalafil at reduced dose is permitted; vardenafil is not)
• You have stable arrhythmias managed with Class I or III antiarrhythmics
• You prefer avoiding food-timing restrictions

Prefer vardenafil if:

• Back pain or myalgia from tadalafil is intolerable and you need a shorter window
• You want faster onset with Staxyn ODT and do not need meals to align
• Your cardiovascular profile has been cleared and antiarrhythmics are not part of your regimen
• You do not have BPH-LUTS requiring dual management

Neither drug works in all patients. Approximately 30 to 35% of men with ED do not respond adequately to their first PDE5 inhibitor regardless of which one is chosen [16]. A failed trial of one agent at maximum tolerated dose, taken correctly with adequate sexual stimulation, justifies a switch to the other before concluding the entire class is ineffective.

Safety in Special Populations

Cardiovascular Disease

The Princeton Consensus (III) guidelines state that men in the low-risk category, stable angina without recent events, controlled hypertension, mild heart failure, can initiate PDE5 inhibitor therapy without further cardiac workup [17]. Intermediate- and high-risk patients require cardiology evaluation before prescribing either drug [17]. Both tadalafil and vardenafil are absolutely contraindicated for men who had a myocardial infarction or stroke within the past 90 days, have resting hypotension below 90/50 mmHg, or have unstable angina [7, 8].

Retinal Disease

Men with hereditary degenerative retinal disorders, particularly retinitis pigmentosa, carry an increased theoretical risk from PDE6 inhibition. The FDA label for vardenafil explicitly flags this population [8]. Tadalafil's lower PDE6 affinity makes it theoretically safer in this group, though clinical data are limited and specialist ophthalmology input is advised before prescribing any PDE5 inhibitor [4].

Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Post-marketing surveillance for all PDE5 inhibitors has identified rare cases of NAION, a sudden loss of vision in one eye [7, 8]. The absolute incidence is low, but men with a prior episode of NAION in one eye should be counseled that the risk in the fellow eye may increase with any PDE5 inhibitor [7]. This warning applies equally to tadalafil and vardenafil.

Side-Effect Frequency Table: Tadalafil vs Vardenafil at Standard Doses

| Adverse Event | Tadalafil 10 to 20 mg | Vardenafil 10 to 20 mg | |---|---|---| | Headache | 11 to 15% | 15 to 21% | | Flushing | 4 to 11% | 10 to 14% | | Nasal congestion | 3 to 9% | 9 to 11% | | Dyspepsia | up to 10% | 1 to 4% | | Back pain/myalgia | 5 to 6.5% | <2% | | Dizziness | 2 to 3% | 2 to 4% | | Visual disturbance | <1% | 1 to 2% | | QTc prolongation | not reported | dose-dependent, ~8 ms at 10 mg |

Sources: FDA prescribing information for tadalafil [7] and vardenafil [8]; Brock et al. [10]; Porst et al. [13].